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                                                                       A Randomized, Double-Blind Study of Larazotide 
Acetate to Prevent the Activation of Celiac Disease 
During Gluten Challenge       
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        L.A.             Arterburn    ,     PhD      4      ,      8            ,         B.M.             Paterson    ,     MD      4      ,      9            ,         Z.H.             Lan    ,     PhD      4      ,      10             and         J.A.             Murray    ,     MD      5                                           
    OBJECTIVES:       In patients with celiac disease, enteropathy is caused by the entry of gluten peptides into 
the lamina propria of the intestine, in which their immunogenicity is potentiated by tissue 
transglutaminase (tTG) and T-helper type 1  –  mediated immune responses are triggered. 
Tight junction disassembly and paracellular permeability are believed to have an important role 
in the transport of gluten peptides to the lamina propria. Larazotide acetate is a tight-junction 
regulator peptide that,   in vitro  , prevents the opening of intestinal epithelial tight junctions. 
The aim of this study was to evaluate the efﬁ  cacy and tolerability of larazotide acetate in 
protecting against gluten-induced intestinal permeability and gastrointestinal symptom severity 
in patients with celiac disease. 
    METHODS:       In this dose-ranging, placebo-controlled study, 86 patients with celiac disease controlled through 
diet were randomly assigned to larazotide acetate (0.25, 1, 4, or 8    mg) or placebo three times per 
day with or without gluten challenge (2.4    g  /  day) for 14 days. The primary efﬁ  cacy outcome was the 
urinary lactulose  /  mannitol (LAMA) fractional excretion ratio. Secondary endpoints included 
gastrointestinal symptom severity, quality-of-life measures, and antibodies to tTG. 
    RESULTS:       LAMA measurements were highly variable in the outpatient setting. The increase in LAMA ratio 
associated with the gluten challenge was not statistically signiﬁ  cantly greater than the increase 
in the gluten-free control. Among patients receiving the gluten challenge, the difference in the 
LAMA ratios for the larazotide acetate and placebo groups was not statistically signiﬁ  cant. However, 
larazotide acetate appeared to limit gluten-induced worsening of gastrointestinal symptom sever-
ity as measured by the Gastrointestinal Symptom Rating Scale at some lower doses but not at the 
higher dose. Symptoms worsened signiﬁ  cantly in the gluten challenge  –  placebo arm compared with 
the placebo  –  placebo arm, suggesting that 2.4    g of gluten per day is sufﬁ  cient to induce reproduc-
ible gluten toxicity. Larazotide acetate was generally well tolerated. No serious adverse events were 
observed. The most common adverse events were headache and urinary tract infection. 
    CONCLUSIONS:       LAMA variability in the outpatient setting precluded accurate assessment of the effect of larazotide 
acetate on intestinal permeability. However, some lower doses of larazotide acetate appeared to 
prevent the increase in gastrointestinal symptom severity induced by gluten challenge.     
    SUPPLEMENTARY MATERIAL   is linked to the online version of the paper at   http://www.nature.com/ajg     
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  INTRODUCTION 
  Celiac disease is one of the most common autoimmune disorders, 
aff  ecting 1  %   of individuals in many regions (  1  –  4  ). Subjects with 
celiac disease frequently present with intestinal symptoms such as 
diarrhea, abdominal pain and bloating, and may also experience 
extraintestinal signs (  5  –  9  ). Severe complications of celiac disease 
include gastrointestinal carcinoma and T-cell lymphoma, which 
may develop owing to chronic infl  ammation and sustained activa-
tion of intestinal lymphocytes and T cells (  10  ). 
  Disease activity is triggered and sustained by the entry of gluten 
peptides into the lamina propria of the intestine aft  er crossing the 
epithelial barrier. Gluten, an amorphous mixture of proteins found 
in the endosperm of cereals like wheat, rye, and barley, is a major 
component of the human diet. In the lamina propria, tissue trans-
glutaminase (tTG) modifi  es gluten peptides and potentiates their 
immunogenicity. Th   ese events subsequently trigger both T-helper 
type 1  –  mediated immune responses (  11  ). 
  Currently, the only management option for patients with celiac 
disease is strict adherence to a gluten-free diet. Adherence to 
this highly restrictive diet is diffi   cult due to the pervasiveness of 
gluten in foods. Patients maintaining a gluten-free diet may still 
be inadvertently exposed to up to 2      g per day of gluten (  12  –  15  ). 
Exposure even to small amounts (i.e., 50     mg per day) can trigger 
signs and symptoms of celiac disease ( 4,14,16 ). Consequently, even 
aft  er long-term maintenance of a gluten-free diet, many patients 
still have symptoms and  /  or mucosal damage (  2,17  –  19  ). Th  erefore, 
a gluten-free diet alone may be insuffi   cient to fully control the 
disease in some patients, and safe and eff  ective pharmacological 
therapy are needed (  20,21  ). 
  Immune responses in patients with celiac disease are initiated 
when immunogenic, incompletely digested gluten peptides gain 
entry into the lamina propria of the small intestine by transcellular 
transport (  22  –  25  ) and  /  or through the paracellular space between 
epithelial cells ( 23,24 ). In transcellular transport, partially degraded 
gliadin moves through epithelial cells in an immunoglobulin-medi-
ated process, making them available for antigen presentation (  24  ). 
Paracellular transport of gliadin peptides occurs in the setting of 
increased paracellular permeability in patients with celiac disease 
due to gliadin-induced innate and adaptive immune responses 
( 11,26 – 28 )  and  subsequent  tight  junction  disassembly  ( 28 – 30 ).  In 
addition, genetic defects have been identifi  ed in the cytoskeletal 
proteins involved in tight junction functioning (  31  –  33  ). 
  Larazotide acetate (formerly referred to as AT-1001) is a fi  rst-
in-class, tight-junction regulator peptide that   in vitro   prevents the 
opening of intestinal epithelial tight junctions induced by multiple 
stimuli, including cytokines, bacterial antigens, and gluten pep-
tides (  34,35  ). Its immunological activity is limited to the luminal 
surface of the small intestine (  36,37  ). In an inpatient, randomized, 
double-blind, placebo-controlled, single-dose study   37)  , patients 
who received larazotide acetate had a signifi  cant reduction in gas-
trointestinal symptoms, particularly diarrhea, aft  er a 2.5-g gluten 
challenge compared with those who received placebo. In addi-
tion, patients in the placebo group had a 70  %   increase in the uri-
nary lactulose-to-mannitol (LAMA) ratio, a measure of intestinal 
permeability, whereas those receiving larazotide acetate had no 
change. Larazotide acetate was not detected in the plasma aft  er 
supra-therapeutic doses, and no signifi  cant  systemic  toxicities 
were observed. 
 Th   is dose-ranging, exploratory study was designed to evaluate 
the eff  ect of multiple doses of larazotide acetate in patients with 
celiac disease who were given a 2-week gluten challenge in an out-
patient setting. In addition, we sought to evaluate the tolerability 
of multiple doses of larazotide acetate, to explore elements of the 
design of studies involving controlled gluten challenges, and to 
gain experience with experimental outcome measures for drug 
development in celiac disease.     
  METHODS 
 Th   e study protocol was approved by the institutional review boards 
of the participating institutions and all patients provided written 
informed consent (ClinicalTrials. gov Identifi  er: NCT00362856). 
Th  e study was conducted at 10 clinical sites in the United States 
between August 2006 and March 2007. Patients were recruited by 
the investigators directly and through peer-to-peer communication.   
  Patients 
  Patients aged 18 to 65 years were eligible for the study if they 
had a body mass index between 18.5 and 38      kg  /  m  2   and a diag-
nosis of celiac disease confi  rmed via biopsys   ≥  6 months before 
study entry. Patients must have been following a gluten-free diet 
for   ≥  6 months before study entry and have been in remission, 
as measured by antibodies to tTG (  ≤  10 ELISA (enzyme-linked 
immunosorbent assay) Units (EU) for IgA and IgG, with 10 EU as 
the cutoff   level for a positive test result). Women must have been 
post-menopausal or surgically sterile or must have had a negative 
result on the serum   β  -human chorionic gonadotropin pregnancy 
test and agreed to use acceptable methods of contraception. 
 Patients were excluded if they had any food intolerances or aller-
gies other than to gluten that would have interfered with the con-
duct of the study, had any chronic active gastrointestinal disease 
other than celiac disease, had diabetes mellitus, were receiving any 
medications that could have interfered with LAMA testing or other 
study measures, used nicotine-containing products for 6 months 
before study entry, had clinically signifi  cant abnormal laboratory 
test results at the time of screening, had signifi  cant comorbidities 
(including positive HIV, hepatitis B surface antigen, or hepatitis C 
test results), were pregnant or breast-feeding mothers, had donated 
blood within 56 days of randomization or plasma     within 7 days, 
had abused alcohol or drugs within 2 years of randomization, had 
a positive urine drug test result at screening, or had participated in 
any clinical trial with an active drug within 30 days of randomiza-
tion. Alcohol consumption of   ≥ 3  fl  uid ounces within 48     h of pro-
ducing urine samples for LAMA ratio testing was not permitted.     
  Study design and dosing 
  In this prospective, multicenter, double-blind trial, 86 patients 
were randomly assigned to one of seven treatment groups 
 ( Figure 1a  ). Patients in four groups received a gluten challenge 
along with doses of 0.25, 1, 4, or 8      mg larazotide acetate three The American Journal of GASTROENTEROLOGY  VOLUME 107 | OCTOBER 2012   www.amjgastro.com
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times daily. Th   e other three groups were a safety control arm with 
the highest dose of larazotide acetate (8     mg) and no gluten chal-
lenge, a gluten-free control arm of patients in remission (placebo 
drug / placebo gluten), and a gluten challenge control arm (placebo 
drug / gluten  challenge). 
 Th  e study treatment regimen started with breakfast on day 1 
and continued through day 14. Patients ingested study medication 
capsules three times daily 15     min before meals. Larazotide acetate 
capsules contained enteric-coated multi-particulate beads. Placebo 
drug was provided in similarly colored capsules, with beads that 
were composed like those of the active drug except for the absence 
of larazotide acetate. Neither larazotide acetate nor placebo drug 
capsules contained gluten. 
 Th   e gluten challenge consisted of two capsules of gluten 400     mg 
(Amgluten 160 powder, Tate and Lyle of Decatur, Illinois, consist-
ing of 45  %   gliadin, 45  %   glutenins, and 10  %   globulins). Matching 
placebo gluten capsules consisted of 100  %   cornstarch. Gluten 
  challenge or placebo was ingested three times daily during meals. 
Th  us, the gluten challenge consisted of a total of 2.4      g per day. 
Patients were asked to eat three meals per day and remain on a 
gluten-free diet during the study.     
  Study conduct and assessments 
 Th  is study was performed according to good clinical practice 
guidelines established by the International Conference on Har-
monization of Technical Requirements for Registration of Phar-
maceuticals for Human Use. Th   ere were fi  ve clinic visits: screening 
and days 0, 7, 14, and 21. 
  An experimental biomarker, the urinary LAMA fractional excre-
tion ratio, was used to quantify changes in intestinal permeability. In 
patients with celiac disease, mucosal injury leads to a simultaneous 
reduction in the transmembrane absorption of monosaccharides 
(e.g., mannitol) and an increase in the  paracellular absorption of dis-
accharides (e.g., lactulose), resulting in an increase in the LAMA ratio. 
Larazotide acetate administered orally 3 times daily before meals. Gluten challenge: 800 mg administered 3 times with meals.
14-Day treatment period
double blind
21-Day
screening period
a
Day 21
end of study
Gluten challenge control
Gluten-free control
Gluten-free safety control
Active treatment arms
with gluten challenge
Placebo drug/gluten
Randomization
Placebo drug/placebo gluten
8 mg larazotide acetate/placebo gluten
0.25 mg larazotide acetate/gluten
1 mg larazotide acetate/gluten
4 mg larazotide acetate/gluten
8 mg larazotide acetate/gluten
LAMA mesurements:
86 Patients
assigned to treatment
12 Patients
0.25 mg Larazotide/
gluten
12 Patients
8 mg Larazotide/
placebo gluten
12 Patients
1 mg Larazotide/
gluten
12 Patients
4 mg Larazotide/
gluten
12 Patients
8 mg Larazotide/
gluten
0 Patients 
discontinued
1 Patient 
discontinued
- 1 protocol violation
2 Patients 
discontinued
- 2 other resons
1 Patient 
discontinued
- 1 other resons
       2 Patient 
       discontinued
- 1 adverse event
- 1 protocol violation
0 Patients 
discontinued
0 Patients 
discontinued
14 Patients
placebo drug/gluten
12 Patients
completed study
12 Patients
completed study
12 Patients
completed study
10 Patients
completed study
11 Patients
completed study
12 Patients
completed study
11 Patients
completed study
12 Patients
placebo drug/
placebo gluten
Urine collected in clinic on day 0 and overnight before days 7, 14, and 21
b
      Figure 1  .                 Schema of overall study design and participant allocation. (  a  ) Study design and (  b  ) disposition of     patients. LAMA, lactulose  /  mannitol.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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A probe solution containing 7.5      g lactulose and 2      g mannitol in 
approximately 100   ml of water was administered orally in the clinic on 
day 0 and in the evening before the study visits on days 7, 14, and 21. 
On the day-0 collection in the clinic, urine was collected for 6      h. 
Patients fasted for at least 4     h before drinking the sugar solution and 
did not eat or drink (except water) until the end of the 6-h collec-
tion. For the overnight collections before days 7, 14, and 21, patients 
were asked to have a normal dinner around 1800hrs, not to eat or 
drink aft  erward (except water until 2200 hrs), void completely at 
2200 hrs, drink the sugar solution, fast overnight (drinking water 
was permitted), and collect their overnight and morning urine. 
Urine samples were frozen at the clinic and stored for analysis of lac-
tulose and mannitol using standardized methods (Dionex   MA-1 ion 
exchange column with pulsed amperometric detection on a Dionex 
Ion Chromatograph 3000, Th  ermo  Scientifi  c, Sunnyvale, CA) (  38  ). 
  Serum was analyzed at a central laboratory for antibodies to tTG 
at screening and day 21 (ACM Medical Laboratory, Rochester, 
New York). 
  Patients completed the Gastrointestinal Symptom Rating Scale 
(GSRS)  ( 39 – 41 )  and  the  Psychological General Well-Being Index 
( 42,43 ) on days 0, 7, 14, and 21. Th   e GSRS is a widely used question-
naire completed by the patient to assess gastrointestinal symptom 
severity. Th   e instrument consists of 15 questions that are grouped 
into fi  ve domains (diarrhea, abdominal pain, indigestion, consti-
pation, and refl  ux). In a   post hoc   analysis, the three domains that 
are most relevant to celiac disease (diarrhea, abdominal pain, and 
indigestion) were evaluated separately, hereaft  er referred to as the 
Celiac Disease GSRS (CeD-GSRS). Both the GSRS (  42,44,45  ) and 
the Psychological General Well-Being Index (  42,46,47  ) have been 
previously used to evaluate patients with celiac disease. However, 
the CeD-GSRS has not been previously used. 
  Tolerability was evaluated at each visit by adverse event surveil-
lance, measurement of vital signs, and clinical laboratory analysis 
for blood chemistry, hematology, and urinalysis. Twelve-lead elec-
trocardiograms were performed at screening and on days 0 and 21. 
Plasma levels of larazotide acetate and metabolites were measured 
on days 0, 7, and 14 using validated high-performance liquid chro-
matography with tandem mass spectrometry, with a lower limit of 
quantifi   cation  of  0.5   ng / ml. 
  In order to diff  erentiate adverse events that were related to the 
gluten challenge from those that were related to study medication, 
the following events were identifi  ed   a priori   as the signs and symp-
toms of gluten toxicity: abdominal discomfort, dyspepsia, nausea, 
diarrhea, vomiting, fl  atulence, constipation, and rash  /  dermatitis 
herpetiformis. Th   ese events were evaluated as part of the effi   cacy 
assessment and were not included in the assessment of safety.     
  Outcome measures and statistical analysis 
 Th   e primary outcome measure was the change in LAMA ratios 
from day 0 to day 14, which was calculated by dividing the LAMA 
ratio at day 14 by the LAMA ratio at day 0. Th  is calculation 
results in a fold-ratio that indicates the intestinal permeability, 
with a ratio of 1 indicating no change in permeability, a ratio        >       1 
  indicating an increase in permeability, and a ratio        <       1 indicating 
a reduction. LAMA values were log-transformed for the analysis 
and sample-size calculations that made it possible to use standard 
sample-size calculation methods for determining the diff  erences 
between the treatment groups. Because of the log transformation, 
LAMA values were summarized using the geometric mean. 
  All analyses presented in this report were conducted using the 
intent-to-treat population. All analyses were pre-specifi  ed unless 
otherwise indicated. Safety analyses were descriptive in nature. 
  In the sample-size calculation, it was estimated that eight evalu-
able patients per group would have provided 80 %  power to demon-
strate a statistically signifi  cant diff  erence (  α     =    0.05)  between  the 
gluten-challenge control group and the larazotide acetate groups 
that received the gluten challenge. An additional 3  –  5 patients 
per group was projected to allow for screen failures and patients 
who  withdrew  during  the  study  (27 – 45 % ).  Th  e  eff  ect size for this 
outcome was set   a priori   at a threefold reduction in LAMA ratios 
between any test group and placebo. Th   e sample size calculation 
was based on a   t   test for diff  erences between two groups. Th  e 
standard deviation for log-transformed fold-ratios was assumed to 
be 0.3, based on the results of a previous study (  37  ).       
  RESULTS   
  Demography and patient disposition 
  Eighty-six patients signed the informed consent, were randomly 
assigned to treatment, and were included in the intent-to-treat 
analysis (  Figure 1b ).  Fift  y-three percent were women, and the 
mean age was 46.3 years. All patients except one were Cauca-
sian. Eighty patients (93.0  %  ) completed the study. Six patients 
discontinued the study prematurely: 1 in the larazotide acetate 
8      mg  /  placebo gluten arm (because of abdominal discomfort), 2 
in the placebo drug  /  gluten-challenge arm (1 positive drug screen 
and 1 allergic reaction), 2 in the larazotide acetate 1     mg  /  gluten-
challenge arm (headache, nausea, fl  atulence, and diarrhea), and 1 
in the larazotide acetate 4     mg  /  gluten-challenge arm (non-compli-
ance with intestinal permeability tests and questionnaires).     
  Primary efﬁ  cacy outcome: LAMA ratio 
 Th  e geometric mean change in the LAMA ratio in the gluten-
challenge control group was greater than that of patients in 
the gluten-free control group, although the diff  erence between the 
groups was not statistically signifi  cant (  Figure 2  ). Among the 
patients who received the gluten challenge, no statistically signifi  -
cant diff  erences in the LAMA ratios were observed between the 
larazotide acetate groups and the placebo group (  Figure 2 ).  Th  e 
LAMA ratios varied widely. Geometric mean LAMA fold-ratios 
numerically decreased between baseline and day 7 in the gluten-
free control groups and the gluten-challenge control group (see 
  Supplementary Figure S1   online).   
  Secondary efﬁ  cacy outcomes 
 Th  e changes in total GSRS and the CeD-GSRS for the each 
  treatment group from baseline to day 14 are shown in   Figure 3 . 
Gastrointestinal symptoms were stable in the two treatment 
groups that received placebo gluten, but symptoms grew more 
severe in the gluten-challenge control group. The American Journal of GASTROENTEROLOGY  VOLUME 107 | OCTOBER 2012   www.amjgastro.com
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by larazotide acetate, was demonstrated using both the GSRS and 
the CeD-GSRS in this study. 
  To complement the analysis of the eff  ect of larazotide acetate 
on symptom severity, each sub-domain of the GSRS (diarrhea, 
abdominal pain, indigestion, constipation, and refl  ux) was ana-
lyzed individually (see   Supplementary Figure S2   online). Based 
on a comparison of the gluten-challenge control to the groups not 
receiving gluten, the gluten challenge resulted in an increase in the 
severity of diarrhea, abdominal pain, and indigestion, with the larg-
est increase in symptom severity in the indigestion domain. Lara-
zotide acetate provided a statistically signifi  cant protection against 
an increase in severity of abdominal pain, indigestion, and refl  ux, 
while the protection against an increase in the severity of diarrhea 
nearly reached statistical signifi  cance (  P     =    0.051).  Although  there 
was an increase in the severity of both the constipation and refl  ux 
domains in the gluten-challenge control group, these increases did 
  Gastrointestinal symptoms in patients who received the larazo-
tide acetate and the gluten challenge did not become as severe as 
they did in the gluten-challenge control group. Th   e 0.25 and 4.0   mg 
doses of larazotide acetate showed statistically signifi  cant preven-
tion of gastrointestinal symptom severity worsening. Th   e 4- and 
8-mg doses of larazotide acetate did not show statistically signifi  -
cant prevention of gastrointestinal symptom severity worsening 
(  P     =    0.067  and  0.329,  respectively).  Results  for  the  CeD-GSRS  were 
generally similar to those of the total GSRS. 
 Because the individual treatment groups were small (  ≤ 13 patients 
per group) and there were similar trends among the groups receiv-
ing larazotide acetate and the gluten challenge, the groups were 
combined into a single active treatment group (  n     =    48) to make pos-
sible further analysis of symptoms and simplify data presentation for 
subsequent exploratory analyses. Likewise, the two groups receiving 
placebo gluten along with either placebo drug or 8      mg larazotide 
acetate were pooled into an aggregate gluten-free control group 
(  n     =    20).  Th  e gluten-challenge control group (  n     =    13)  indicates  the 
response to gluten ingestion in the absence of larazotide acetate. 
  Figure 4  shows the time course of the change in the GSRS scores 
for these combined treatment groups. In the gluten-challenge con-
trol group, the severity of gastrointestinal symptoms increased sub-
stantially during the gluten-challenge period (baseline to day 14), 
as measured by both the total GSRS and the CeD-GSRS. Th  e  scores 
rapidly decreased aft  er the challenge was over (day 14 to day 21). 
By contrast, there was no increase in severity in the groups that 
did not receive the gluten challenge (gluten-free control), and only 
a modest increase in the patients who received larazotide acetate 
and the gluten challenge. Symptoms were statistically signifi  cantly 
less severe in both the gluten-free control group and the group 
  consisting of patients who received larazotide acetate and the 
 gluten  challenge compared with the gluten-challenge control group 
(  P     <    0.05).  Th  us, an increase in symptom severity in response to 
gluten, as well as protection from the exposure to gluten provided 
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acetate  /  gluten-challenge (G) groups to the placebo (P) drug  /  gluten-challenge 
group were calculated using an analysis of covariance model, with treatment 
as a ﬁ  xed effect and the corresponding baseline value as a covariate.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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not appear to be specifi  cally attributable to gluten, as there were 
similar increases in the gluten-free control group. 
  No statistically signifi  cant diff  erence between the larazotide ace-
tate groups and the gluten-challenge control group was observed 
in changes in the total Psychological General Well-Being Index 
scores (see   Supplementary Table 1   online). 
  Changes in the weekly means of the number of bowel move-
ments, number of episodes of diarrhea, stool consistency rating, 
and abdominal discomfort scores from daily bowel diaries are pro-
vided in   Supplementary Figure S3   online. In general, daily bowel 
diary scores for patients in the larazotide acetate 1-mg and 0.25-
mg groups did not increase as much as those in the other groups 
exposed to gluten. 
  At two of four tested doses, larazotide acetate appeared to pro-
tect patients from the signs and symptoms of gluten toxicity, which 
were defi  ned   a priori  : abdominal discomfort, dyspepsia, nausea, 
diarrhea, vomiting, fl   atulence, constipation, or rash  /  dermatitis 
herpetiformis. Compared with the gluten-challenge control, in 
which 50.0  %   of patients experienced symptoms of gluten toxicity, 
20.8  %   of participants in both the aggregated gluten-free control 
and the larazotide acetate treatment arms exhibited these symp-
toms (  P     =    0.11  and   P     =    0.046,  respectively;  Fisher ’ s  exact  test).  Aft  er 
other signs and symptoms that were determined   post hoc   likely to 
be related to gluten toxicity were included (namely, elevated liver 
function tests and aphthous stomatitis), 64.3  %   of participants in 
the gluten-challenge control were aff  ected, compared with 16.7  %   
in the aggregated gluten-free control and 23.3  %   in the aggregated 
larazotide acetate treatment arms (  P     =    0.021  and   P     =    0.008,  respec-
tively; Fisher  ’  s exact test). 
  Mean titers at screening for antibodies to tTG ranged from 
1.6 to 3.0      U  /  ml, and no signifi  cant diff  erences between the treat-
ment groups were observed at screening. No signifi  cant diff  er-
ences between the treatment groups were observed in the mean 
changes from screening to day 21 in the titers of antibodies to tTG 
(    −    0.1   U / ml in the combined gluten-free control group, 2.9   U / ml in 
the gluten-challenge control group ( P     =    0.204 vs. gluten-free control 
group), and 0.9      U  /  ml in the combined larazotide acetate  /  gluten-
challenge groups (  P     =    0.256  vs.  gluten-challenge  control  group).   
  Tolerability 
 Th  e multiple oral doses of larazotide acetate used in this study 
were well tolerated. Of the 86 patients in the intent-to-treat popu-
lation, 44 (51.2  %  ) had at least one treatment-emergent adverse 
event (  Table 1 ).  Fift  een of the 60 patients who received larazotide 
acetate (25.0 % ) had adverse events that the investigator considered 
to be related to study medication, while 7 of the 26 patients who 
received placebo drug (26.9  %  ) had such events. Headache was the 
most common adverse event, reported by 17 patients, with no dif-
ferences among treatment groups. None of the patients had serious 
adverse events. Th  ere were also no clinically signifi  cant fi  ndings 
of hepatic, bone, or renal toxicity. Vital signs, electrocardiogram, 
hematology, and clinical chemistry parameters showed no changes 
from baseline that were considered clinically signifi  cant. 
  Five (5.8  %  ) patients had urinary tract infections, all of which 
occurred in patients who received larazotide acetate and the gluten 
challenge. Th   ere was no evidence of a dosage eff  ect or an associa-
tion to the duration of dosing at the onset of the event. Micro-
biological confi  rmation was attempted in only one of these events, 
and the result was negative. Only one patient received antibiotic 
Gluten-challenge control
Gluten-challenge control
Gluten-free control
P=0.013
1.0 a
P=0.032
Larazotide acetate + gluten challenge
0.8
0.6
0.4
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
t
o
t
a
l
 
G
S
R
S
 
s
c
o
r
e
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
t
o
t
a
l
 
C
e
D
-
G
S
R
S
 
s
c
o
r
e
0.2
0.0
–0.2
Gluten challenge
P=0.019
1.0
P=0.016
Gluten-free control
Larazotide acetate + gluten challenge
–0.4
–0.6 0 7 14 21
0.8
0.6
0.4
0.2
0.0
–0.2
–0.4
–0.6 07
Gluten challenge
14 21
b
    Figure 4  .                 Change in gastrointestinal symptoms as measured by the GSRS and 
CeD-GSRS during and after gluten challenge in the gluten challenge/placebo 
drug cohort compared to the aggregated gluten-free control cohorts and the 
Larazotide-treated gluten challenge groups. Time course of mean change from 
baseline in the total (  a  ) Gastrointestinal Symptom Rating Scale (GSRS) score 
and (  b  ) Celiac Disease (CeD-GSRS) scores. The gluten control group includes 
patients who received placebo drug and the gluten challenge (  n        =      13). Gluten-
free control includes patients who received placebo drug or 8    mg larazotide 
acetate and gluten placebo (  n        =      20). Patients who received larazotide acetate 
and the gluten challenge were also combined into one group (  n        =      38).   P   val-
ues were calculated using an analysis of covariance model with treatment as 
a ﬁ  xed effect and the corresponding baseline value as a covariate.   The American Journal of GASTROENTEROLOGY  VOLUME 107 | OCTOBER 2012   www.amjgastro.com
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the signifi  cant variability in the LAMA ratios in the outpatient 
  setting should be taken into account in future studies utilizing this 
outcome. Sample size calculations used in the design of this study 
were based on one preliminary inpatient trial in which the eff  ects 
of gluten challenge and drug treatment were larger than those 
observed in this study. Although we cannot exclude the possibility 
that the primary effi   cacy outcome in this study was not reached 
because the treatment did not produce an eff  ect, it is likely that the 
methods used did not fully detect an eff  ect of both the gluten chal-
lenge and the larazotide acetate therapy. 
  In contrast to the LAMA fi  ndings, the results of gastrointestinal 
symptom severity assessments indicate that larazotide acetate pro-
vided protection against the increase in symptoms associated with a 
gluten challenge in patients with celiac disease. Both the prespecifi  ed 
total GSRS and the exploratory CeD-GSRS scores of patients who 
received placebo drug increased following the gluten challenge. How-
ever, at two of four tested doses (0.25 and 4   mg), patients who received 
larazotide acetate and the gluten challenge did not show such increases 
in GSRS and CeD-GSRS scores. Symptom severity was statistically sig-
nifi  cantly lower than placebo drug in these treatment groups. 
  As expected, most patients who received the gluten challenge, 
including those in the gluten-challenge control group, did not develop 
antibodies to tTG. Th   us, the eff  ect of larazotide acetate on antibodies 
to tTG could not be assessed. Longer gluten challenge studies and / or 
higher gluten doses will be necessary to assess the eff  ect of the lara-
zotide acetate on the development of antibodies to tTG. 
  In conclusion, larazotide acetate was well tolerated in this popu-
lation of patients with celiac disease. Larazotide acetate prevented 
the increase in gastrointestinal symptom severity induced by glu-
ten challenge at two of the four doses tested. A gluten challenge of 
2.4      g per day was suffi   cient to evaluate this outcome. Additional 
studies with appropriate run-in periods, larger study populations, 
additional measures such as histology, and longer duration may 
be warranted to further evaluate the eff  ect of larazotide acetate in 
patients  with  celiac  disease.       
medication. All cases were mild, and none were considered to be 
related to study drug. 
  Plasma levels of larazotide acetate were measured at days 0, 7, 
and 14 and were below the limit of quantifi   cation  (0.5   ng / ml)  in  all 
the groups. Metabolites were measured in the highest dose group 
(8     mg) and were also below the lower limit of quantifi   cation.    
  DISCUSSION 
 Th   e purpose of the study was to evaluate the effi   cacy and tolerability 
of multiple doses of larazotide acetate in preventing the exacerba-
tion of symptoms aft  er a gluten challenge in patients with celiac dis-
ease well controlled through a gluten-free diet. Th  e  primary  effi   cacy 
outcome was the LAMA ratio, which was used as an experimental 
biomarker for intestinal permeability. Th   e results indicate that the 
gluten challenge induced both an increase in symptoms as measured 
by the GSRS and intestinal permeability in patients who received 
placebo drug, as indicated by an increase in the LAMA ratio; how-
ever, this increase was not statistically signifi  cant. LAMA ratios for 
patients who received larazotide acetate and the gluten challenge 
were also not statistically signifi  cantly diff  erent from those who 
received placebo and the gluten challenge. Th  e  signifi  cant deterio-
ration in gastrointestinal symptoms in the group receiving gluten 
and placebo compared with the group receiving no gluten suggests 
that 2.4     g of gluten per day is suffi   cient to induce measurable and 
clinically important symptoms in clinical trial settings. 
 LAMA ratio values varied markedly among all treatment groups, 
which may be the result of conducting the measurements in an 
outpatient setting. In addition, a decrease in LAMA was observed 
in most treatment groups at day 7, including the gluten-free con-
trol group, in which patients received both placebo drug and pla-
cebo gluten. Th   ese results suggest that there may have been a study 
eff  ect, by virtue of which patients were more compliant with their 
gluten-free diets while participating in the study. Future studies 
should include a run-in period for diet stabilization. In addition, 
    Table 1  .       Summary of adverse events 
        Category       Gluten-free control       Gluten challenge   
           Placebo (  n   = 12)      8    mg (  n   = 12)      Placebo (  n   = 14)      0.25    mg (  n   = 12)      1    mg (  n   = 12)      4    mg (  n   = 12)      8    mg (  n   = 12)  
      Patients with   ≥  1 adverse event    5 (41.7)    4 (33.3)    7 (50.0)    7 (58.3)    8 (66.7)    6 (50.0)    7 (58.3) 
      Patients with   ≥  1 adverse event 
related to study medication    a     
  2 (16.7)    1 (8.3)    5 (35.7)    3 (25.0)    4 (33.3)    3 (25.0)    4 (33.3) 
      Patients with   ≥  1 severe 
adverse event 
  1 (8.3)    0 (0.0)    0 (0.0)    0 (0.0)    2 (16.7)    0 (0.0)    0 (0.0) 
      Patients with   ≥  1 serious 
adverse events 
  0 (0.0)    0 (0.0)    0 (0.0)    0 (0.0)    0 (0.0)    0 (0.0)    0 (0.0) 
      Patients who discontinued 
study medication because of 
an adverse event 
  0 (0.0)    0 (0.0)    1 (7.1)    0 (0.0)    0 (0.0)    0 (0.0)    0 (0.0) 
        Adverse events that occurred in     ≥    5  %   of patients   
           Headache   4 (33.3)    0 (0.0)    3 (21.4)    3 (25.0)    2 (16.7)    3 (25.0)    2 (16.7) 
           Urinary tract infection    0 (0.0)    0 (0.0)    0 (0.0)    2 (16.7)    1 (8.3)    1 (8.3)    1 (8.3) 
      a        Events that were considered by the investigator to be possibly or probably related to the study medication.     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Study  Highlights  
  WHAT IS CURRENT KNOWLEDGE 
   3  Celiac disease is one of the most common autoimmune 
disorders. 
   3  The gluten-free diet is the only existing management option 
for patients with celiac disease. 
   3  Exposure even to small amounts of gluten can trigger 
intestinal inﬂ  ammation, and symptoms of celiac disease 
often persist or recur despite efforts to maintain a strict 
gluten-free diet. 
  WHAT IS NEW HERE 
   3  Larazotide acetate is a tight-junction regulator that,   in vitro  , 
prevents the opening of intestinal epithelial tight junctions. 
   3  The primary efﬁ  cacy outcome of this study was not met. 
In one of the secondary endpoints, larazotide acetate 
appeared to limit gluten-induced worsening of 
gastrointestinal symptom severity as measured by the 
Gastrointestinal Symptom Rating Scale at some lower does 
but not at the higher dose. Larazotide acetate was generally 
well tolerated by patients with celiac disease who were 
given a gluten challenge.                      
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